Reuters logo
BRIEF-Esperion Therapeutics Q3 loss per share $1.86‍​
November 7, 2017 / 1:38 PM / a month ago

BRIEF-Esperion Therapeutics Q3 loss per share $1.86‍​

Nov 7 (Reuters) - Esperion Therapeutics Inc

* Esperion provides bempedoic acid franchise development program updates; reports third quarter 2017 financial results

* Expects full-year 2017 net cash used in operating activities to be approximately $135 million​

* Expects cash and cash equivalents and investment securities to be approximately $272 million at December 31

* Estimates cash resources are sufficient to fund operations through Q1 2020​

* Qtrly loss per share $1.86‍​

* Q3 earnings per share view $-1.78 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below